Late Breaking Abstract - The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models

M. Niepel (Cambridge, United States), M. Vasbinder (Cambridge, United States), J. Molina (Cambridge, United States), B. Gui (Cambridge, United States), K. Kunii (Cambridge, United States), D. Blackwell (Cambridge, United States), E. Mateer (Cambridge, United States), J. Mo (Cambridge, United States), C. Coutts (Cambridge, United States), N. Perl (Cambridge, United States), K. Kuplast-Barr (Cambridge, United States), W. Church (Cambridge, United States), C. Majer (Cambridge, United States), L. Schenkel (Cambridge, United States), K. Swinger (Cambridge, United States), R. Abo (Cambridge, United States), E. Bamberg (Cambridge, United States), Y. Ren (Cambridge, United States), L. Utley (Cambridge, United States), T. Wigle (Cambridge, United States), C. Reik (Cambridge, United States), A. Lu (Cambridge, United States), A. Cheung (Cambridge, United States), E. Minissale (Cambridge, United States), K. Mceachern (Cambridge, United States), V. Richon (Cambridge, United States), S. Parasuraman (Cambridge, United States), K. Kuntz (Cambridge, United States), H. Keilhack (Cambridge, United States)

Source: International Congress 2022 – Late-breaking abstracts in airway disease

Session: Late-breaking abstracts in airway disease
Session type: Thematic Poster
Number: 4192

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Niepel (Cambridge, United States), M. Vasbinder (Cambridge, United States), J. Molina (Cambridge, United States), B. Gui (Cambridge, United States), K. Kunii (Cambridge, United States), D. Blackwell (Cambridge, United States), E. Mateer (Cambridge, United States), J. Mo (Cambridge, United States), C. Coutts (Cambridge, United States), N. Perl (Cambridge, United States), K. Kuplast-Barr (Cambridge, United States), W. Church (Cambridge, United States), C. Majer (Cambridge, United States), L. Schenkel (Cambridge, United States), K. Swinger (Cambridge, United States), R. Abo (Cambridge, United States), E. Bamberg (Cambridge, United States), Y. Ren (Cambridge, United States), L. Utley (Cambridge, United States), T. Wigle (Cambridge, United States), C. Reik (Cambridge, United States), A. Lu (Cambridge, United States), A. Cheung (Cambridge, United States), E. Minissale (Cambridge, United States), K. Mceachern (Cambridge, United States), V. Richon (Cambridge, United States), S. Parasuraman (Cambridge, United States), K. Kuntz (Cambridge, United States), H. Keilhack (Cambridge, United States). Late Breaking Abstract - The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models. 4192

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.